Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Nonalcoholic Steatohepatitis

BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). The present study evaluated the impact of OCA therapy on lipoprotein sub-particles. METHOD: The study included...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Hepatol
Glavni autori: Siddiqui, Mohammad Shadab, Van Natta, Mark L., Connelly, Margery A., Vuppalanchi, Raj, Neuschwander-Tetri, Brent A., Tonascia, James, Guy, Cynthia, Loomba, Rohit, Dasarathy, Srinivasan, Wattacheril, Julia, Chalasani, Naga, Sanyal, Arun J.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6920569/
https://ncbi.nlm.nih.gov/pubmed/31634532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2019.10.006
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items